Michael C. Dugan, M.D.

Dr. Michael Dugan is an experienced biotech executive, pathologist and laboratory medical director who has worked for several advanced biotech companies, commercial reference laboratories, and both academic and community hospital-based pathology groups. He currently serves as CEO of Seaside Bio, Inc. and as principal of MCDXI Medical Diagnostics, Inc., both involved in diagnostic assay, device, platform and therapeutic development. He has helped develop and/or launch several leading edge diagnostic products related to oncology, especially in neuro-oncology, gastroenterology, cancer screening, cancer staging, and therapy selection, etc., including a quantitative assay for metastatic cancer cells in the cerebrospinal fluid (CSF), a cell-free DNA-based assay for colon cancer screening, a ctDNA assay for colorectal cancer minimal residual disease detection, a gene-expression based test for evaluating tumors of unknown origin, and early companion diagnostic assays [KRAS, EGFR, ALK and BRAF].

Dr. Dugan has specialized in strategic clinical market evaluation, market development, clinical study development, clinical education, as well as medical policy coverage and reimbursement related issues to help bring these products to fruition in clinical use. He has also helped develop and operate numerous CLIA labs, both very large and small, and launched In Vitro Diagnostic (IVD) products such as cobas BRAF and Cologuard. From 2007 to 2011, he managed a 30+ person pathology group for Genzyme Genetics located in New York, Los Angeles and Milan Italy [Dr. Juan Rosai].